Accuracy of the Brief Cognitive Screening Battery for diagnosing Alzheimer's disease defined by cerebrospinal fluid biomarkers and AT(N) classification: a case-control study

Patrícia Regina Henrique Peles; Larissa de Souza Salvador; Leonardo Cruz de Souza; Paulo Caramelli

doi:10.1590/0004-282X-ANP-2021-0012

Arquivos de Neuro-Psiquiatria, Table of Contents

CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2022; 80(01): 23-29
DOI: 10.1590/0004-282X-ANP-2021-0012

Article

Accuracy of the Brief Cognitive Screening Battery for diagnosing Alzheimer's disease defined by cerebrospinal fluid biomarkers and AT(N) classification: a case-control study

Acurácia da Bateria Breve de Rastreio Cognitivo no diagnóstico da doença de Alzheimer definida por biomarcadores no líquido cefalorraquidiano e classificação pelo sistema AT(N): estudo caso-controle

Patrícia Regina Henrique Peles

¹Universidade Federal de Minas Gerais, Programa de Pós-Graduação em Neurociências, Belo Horizonte MG, Brazil.

²Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Clínica Médica, Grupo de Pesquisa em Neurologia Cognitiva e do Comportamento, Belo Horizonte MG, Brazil.

,

Larissa de Souza Salvador

²Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Clínica Médica, Grupo de Pesquisa em Neurologia Cognitiva e do Comportamento, Belo Horizonte MG, Brazil.

³Universidade Federal de Minas Gerais, Faculdade de Medicina, Programa de Pós-Graduação em Ciências Aplicadas à Saúde do Adulto, Belo Horizonte MG, Brazil.

,

Leonardo Cruz de Souza

¹Universidade Federal de Minas Gerais, Programa de Pós-Graduação em Neurociências, Belo Horizonte MG, Brazil.

²Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Clínica Médica, Grupo de Pesquisa em Neurologia Cognitiva e do Comportamento, Belo Horizonte MG, Brazil.

,

Paulo Caramelli

¹Universidade Federal de Minas Gerais, Programa de Pós-Graduação em Neurociências, Belo Horizonte MG, Brazil.

²Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Clínica Médica, Grupo de Pesquisa em Neurologia Cognitiva e do Comportamento, Belo Horizonte MG, Brazil.

³Universidade Federal de Minas Gerais, Faculdade de Medicina, Programa de Pós-Graduação em Ciências Aplicadas à Saúde do Adulto, Belo Horizonte MG, Brazil.

› Author Affiliations

Abstract

ABSTRACT

Background: Validation of cognitive instruments for detection of Alzheimer's disease (AD) based on correlation with diagnostic biomarkers allows more reliable identification of the disease.

Objectives: To investigate the accuracy of the Brief Cognitive Screening Battery (BCSB) in the differential diagnosis between AD, non-AD cognitive impairment (both defined by cerebrospinal fluid [CSF] biomarkers) and healthy cognition, and to correlate CSF biomarker results with cognitive performance. Methods: Overall, 117 individuals were evaluated: 45 patients with mild cognitive impairment (MCI) or mild dementia within the AD continuum defined by the AT(N) classification [A+T+/-(N)+/]; 27 non-AD patients with MCI or mild dementia [A-T+/-(N)+/-]; and 45 cognitively healthy individuals without CSF biomarker results. All participants underwent evaluation using the BCSB. Results: The total BCSB and delayed recall (DR) scores of the BCSB memory test showed high diagnostic accuracy, as indicated by areas under the ROC curve (AUC): 0.89 and 0.87, respectively, for discrimination between AD and non-AD versus cognitively healthy controls. Similarly, total BCSB and DR displayed high accuracy (AUC-ROC curves of 0.89 and 0.91, respectively) for differentiation between AD and controls. BCSB tests displayed low accuracy for differentiation between AD and non-AD. The CSF levels of biomarkers correlated significantly, though weakly, with DR. Conclusions: Total BCSB and DR scores presented good accuracy for differentiation between patients with a biological AD diagnosis and cognitively healthy individuals, but low accuracy for differentiating AD from non-AD patients.

RESUMO

Antecedentes: A validação de testes cognitivos para identificação da doença de Alzheimer (DA) definida por biomarcadores aumenta a confiabilidade diagnóstica.

Objetivos: Investigar a acurácia da Bateria Breve de Rastreio Cognitivo (BBRC) no diagnóstico diferencial entre DA, comprometimento cognitivo não-DA (ambos diagnósticos definidos por biomarcadores no líquido cefalorraquidiano-LCR) e indivíduos cognitivamente saudáveis, e investigar correlações entre desempenho nos testes e concentrações dos biomarcadores no LCR. Métodos: No total, 117 indivíduos foram avaliados. Quarenta e cinco pacientes com comprometimento cognitivo leve (CCL) ou demência leve com diagnóstico do continuum de DA definido pela classificação AT(N) [A+T+/-(N)+/-], 27 pacientes com CCL ou demência leve não-DA [A-T+/-(N)+/-], e 45 controles cognitivamente saudáveis sem estudo de biomarcadores no LCR. Os participantes foram submetidos à BBRC. Resultados: O escore total da BBRC e a evocação tardia (ET) no teste de memória da BBRC apresentaram elevada acurácia diagnóstica na diferenciação entre DA e não-DA versus controles, indicada pelas áreas sob a curva ROC (AUC) de 0,89 e 0,87, respectivamente. De modo semelhante, o escore total da BBRC e a ET mostraram elevadas acurácias (AUC-ROC de 0,89 e 0,91, respectivamente) para o diagnóstico diferencial entre DA e controles. A acurácia da BBRC foi baixa na diferenciação entre DA e não-DA. Os níveis dos biomarcadores no LCR se correlacionaram de forma significativa, embora fraca, com ET. Conclusões: Os escores totais da BCSB e a ET apresentaram boa acurácia na diferenciação entre pacientes com diagnóstico biológico de DA e controles cognitivamente saudáveis, mas baixa acurácia para diferenciar DA de não-DA.

Keywords:

Alzheimer Disease - Cognitive Dysfunction - Diagnosis - Biomarkers - Cognition

Palavras-chave:

Doença de Alzheimer - Disfunção Cognitiva - Diagnóstico - Biomarcadores - Cognição

Full Text

References

References
1 Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M. et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366 9503 2112-2117 https://doi.org/10.1016/S0140-6736(05)67889-0
2 Fiest KM, Jetté N, Roberts JI, Maxwell CJ, Smith EE, Black SE. et al. The prevalence and incidence of dementia: a systematic review and meta-analysis. Can J Neurol Sci 2016; 43 (Suppl. 01) S3-50 https://doi.org/10.1017/cjn.2016.18
3 The Lancet. Alzheimer's disease: expedition into the unknown. Lancet 2016; 388: 10061-2713 https://doi.org/10.1016/S0140-6736(16)32457-6
4 Herrera Jr E, Caramelli P, Silveira ASB, Nitrini R. Epidemiologic survey of dementia in a community-dwelling Brazilian population. Alzheimer Dis Assoc Disord 2002; 16 (02) 103-108 https://doi.org/10.1097/00002093-200204000-00007
5 Nitrini R, Bottino CM, Albala C, Capuñay NSC, Ketzoian C, Rodriguez JJL. et al. Prevalence of dementia in Latin America: a collaborative study of population-based cohorts. Int Psychogeriatr 2009; 21 (04) 622‐30-622‐30 https://doi.org/10.1017/S1041610209009430
6 Callahan CM, Tu W, Stump TE, Clark DO, Unroe KT, Hendrie HC. Errors in self-reports of health services use: impact on alzheimer disease clinical trial designs. Alzheimer Dis Assoc Disord 2015; 29 (01) 75‐81-75‐81 https://doi.org/10.1097/WAD.20210012202100120048
7 Jack Jr CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC. et al. Introduction to the recommendations of the National Institute on Aging-Alzheimer's Association working groups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7 (03) 257-262 https://doi.org/10.1016/j.jalz.2011.03.004
8 Nitrini R, Caramelli P, Bottino CMC, Damasceno BP, Brucki SMD, Anghinah R. Academia Brasileira de Neurologia Diagnosis of Alzheimer's disease in Brazil: diagnostic criteria and auxiliary tests. Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. Arq Neuropsiquiatr 2005; 63 3A 713-719 https://doi.org/10.1590/S0004-282X2005000400033
9 Nitrini R, Lefèvre BH, Mathias SC, Caramelli P, Carrilho PE, Sauaia N. et al. Neuropsychological tests of simple application for diagnosing dementia. Arq Neuropsiquiatr 1994; 52 (04) 457-465 https://doi.org/10.1590/S0004-282X1994000400001
10 Yassuda MS, Silva HS, Lima-Silva TB, Cachioni M, Falcão DVS, Lopes A. et al. Normative data for the brief cognitive screening battery stratified by age and education. Dement Neuropsychol 2017; 11 (01) 48-53 https://doi.org/10.1590/1980-57642016dn11-010008
11 Nitrini R, Caramelli P, Porto CS, Charchat-Fichman H, Formigoni AP, Carthery-Goulart MT. et al. Brief cognitive battery in the diagnosis of mild alzheimer's disease in subjects with medium and high levels of education. Dement Neuropsychol 2007; 1 (01) 32-36 https://doi.org/10.1590/S1980-57642008DN10100006
12 Fichman-Charchat H, Miranda CV, Fernandes CS, Mograbi D, Oliveira RM, Novaes R. et al. Brief Cognitive Screening Battery (BCSB) is a very useful tool for diagnosis of probable mild Alzheimer´s disease in a geriatric clinic. Arq Neuropsiquiatr 2016; 74 (02) 149-154 https://doi.org/10.1590/0004-282X20150202
13 Folstein M, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12 (03) 189-198 https://doi.org/10.1016/0022-3956(75)90026-6
14 Bertolucci PHF, Brucki SMD, Campacci SR, Juliano Y. The Mini-Mental State Examination in a general population: impact of educational status. Arq Neuropsiquiatr 1994; 52 (01) 1-7 https://doi.org/10.1590/S0004-282X1994000100001
15 Albert MS, DeKosky ST, Dickson DW, Dubois B, Feldman HH, Fox NC. et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations by the National Institute on Aging-Alzheimer's Association working groups on diagnostic guidelines for alzheimer's disease. Alzheimers Dement 2011; 7 (03) 270-279 https://doi.org/10.1016/j.jalz.2011.03.008
16 McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH. et al. The diagnosis of dementia due to alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for alzheimer's disease. Alzheimers Dement 2011; 7 (03) 263-269 https://doi.org/10.1016/j.jalz.2011.03.005
17 Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134 (09) 2456-2477 https://doi.org/10.1093/brain/awr179
18 Román GC. Defining dementia: clinical criteria for the diagnosis of vascular dementia. Acta Neurol Scand Suppl 2002; 106 (178) 6-9 https://doi.org/10.1034/j.1600-0404.106.s178.2.x
19 Wetterling T, Kanitz RD, Borgis KJ. Clinical evaluation of the ICD-10 criteria for vascular dementia. Eur Arch Psychiatry Clin Neurosci 1993; 243 (01) 33-40 https://doi.org/10.1007/BF02191521
20 Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF. et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76 (11) 1006-1014 https://doi.org/10.1212/WNL.0b013e31821103e6
21 McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA. et al. Consensus guidelines for the clinical and pathologic diagnosis of Dementia with Lewy Bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47 (05) 1113-1124 https://doi.org/10.1212/WNL.47.5.1113
22 Geser F, Wenning GK, Poewe W, McKeith I. How to diagnose Dementia with Lewy Bodies: state of the art. Mov Disord 2005; 20 (Suppl. 12) S11-S20 https://doi.org/10.1002/mds.20535
23 Amaral-Carvalho V, Caramelli P. Normative data for healthy middle-aged and elderly performance on the Addenbrooke Cognitive Examination-Revised. Cogn Behav Neurol 2012; 25 (02) 72-76 https://doi.org/10.1097/WNN.0b013e318259594b
24 Nitrini R, Lefèvre BH, Mathias SC, Caramelli P, Carrilho PE, Sauaia N. et al. Neuropsychological tests of simple application for diagnosing dementia. Arq Neuropsiquiatr 1994; 52 (04) 457‐65-457‐65 https://doi.org/10.1590/S0004-282X1994000400001
25 Brucki SM, Malheiros SM, Okamoto IH, Bertolucci PH. Normative data on the verbal fluency test in the animal category in our milieu. Arq Neuropsiquiatr 1997; 55 (01) 56-61 https://doi.org/10.1590/S0004-282X1997000100009
26 Shulman K, Gold DP, Cohen CA, Zuchero CA. Clock design and dementia in the community: a longitudinal study. Int J Geriatr Psych 1993; 8 (06) 487-496 https://doi.org/10.1002/gps.930080606
27 Lehmann S, Schraen S, Quadrio I, Paquet C, Bombois S, Dalaby C. et al. Impact of harmonization of collection tubes on alzheimer's disease diagnosis. Alzheimers Dement 2014; 10 (Suppl. 05) S390 94.e2 https://doi.org/10.1016/j.jalz.2013.06.008
28 Hampel H, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I. et al. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ1-42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. Alzheimers Dement 2018; 14 (04) 492-501 https://doi.org/10.1016/j.jalz.2017.11.015
29 Bertoux M, Cassagnaud P, Lebouvier T, Lebert F, Sarazin M, Le Ber I. et al. Does amnesia specifically predict Alzheimer's pathology? A neuropathological study. Neurobiol Aging 2020; 95: 123-130 https://doi.org/10.1016/j.neurobiolaging.2020.07.011
30 Bertoux M, Cassagnaud P, Lebouvier T, Lebert F, Sarazin M, Le Ber I. et al. Does amnesia specifically predict alzheimer's pathology? A neuropathological study. Neurobiol Aging 2020; 95: 123-130 https://doi.org/10.1016/j.neurobiolaging.2020.07.011
31 Nitrini R, Caramelli P, Herrera Júnior E, Porto CS, Charchat-Fichman H, Carthery MT. et al. Performance of illiterate and literate nondemented elderly subjects in two tests of long-term memory. J Int Neuropsychol Soc 2004; 10 (04) 634-638 https://doi.org/10.1017/S1355617704104062
32 Takada LT, Caramelli P, Fichman HC, Porto CS, Bahia VS, Anghinah R. et al. Comparison between two tests of delayed recall for the diagnosis of dementia. Arq Neuropsiquiatr 2006; 64 (01) 35-40 https://doi.org/10.1590/S0004-282X2006000100008
33 Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G. et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD): Part 1. Clinical and neuropsychological assessment of alzheimer's disease. Neurology 1989; 39 (09) 1159-1165 https://doi.org/10.1590/s0004-282x2006000100008
34 Bertolucci PH, Okamoto IH, Brucki SM, Siviero MO, Toniolo Neto J, Ramos LR. Applicability of the CERAD neuropsychological battery to Brazilian elderly. Arq Neuropsiquiatr 2001; 59 3-A 532-536 https://doi.org/10.1590/S0004-282X2001000400009
35 Rolstad S, Berg AI, Bjerke M, Blennow K, Johansson B, Zetterberg H. et al. Amyloid-β₄₂ is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. J Alzheimers Dis 2011; 26 (01) 135-142 https://doi.org/10.3233/JAD-2011-110038
36 Rolstad S, Berg AI, Bjerke M, Johansson B, Zetterberg H, Wallin A. Cerebrospinal fluid biomarkers mirror rate of cognitive decline. J Alzheimers Dis 2013; 34 (04) 949-956 https://doi.org/10.3233/JAD-121960
37 Radanovic M, Oshiro CA, Freitas TQ, Talib LL, Forlenza OV. Correlation between biomarkers in the CSF of Alzheimer's disease and global cognition in a cohort of psychogeriatric clinic. Braz J Psychiatry 2019; 41 (06) 479-484 https://doi.org/10.1590/1516-4446-2018-0296
38 Mazzeo S, Santangelo R, Bernasconi MP, Cecchetti G, Fiorino A, Pinto P. et al. Combining cerebrospinal fluid biomarkers and neuropsychological assessment: a simple and economical algorithm to predict the progression of cognitive impairment leading to Alzheimer's disease dementia. J Alzheimers Dis 2016; 54 (04) 1495-1508 https://doi.org/10.3233/JAD-160360
39 Ferreira D, Perestelo-Pérez L, Westman E, Wahlund L-O, Sarría A, Serrano-Aguilar P. Meta-review of central CSF biomarkers in Alzheimer's disease: the state of the art after the new diagnostic criteria reviewed. Front Aging Neurosci 2014; 6: 47 https://doi.org/10.3389/fnagi.2014.00047